Research programme: transient receptor potential channel inhibitors - Johnson & Johnson

Drug Profile

Research programme: transient receptor potential channel inhibitors - Johnson & Johnson

Alternative Names: 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives - Johnson & Johnson; JNJ 17203212; TRPM8 antagonists - Johnson & Johnson; TRPV1 antagonists - Johnson & Johnson

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Benzimidazoles; Heterocyclic bicyclo compounds; Pyrimidines; Spiro compounds; Thiazoles
  • Mechanism of Action TRPM8 protein inhibitors; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cough; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cough in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO)
  • 26 Aug 2010 Pharmacodynamics data from preclinical studies in pain presented at the 240th American Chemical Society National Meeting (240th-ACS-2010) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top